Supernus Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | $0.36 | $0.39 | $0.38 |
| Q2 2024 | 1 | $0.38 | $0.40 | $0.39 |
| Q3 2024 | 1 | $0.44 | $0.45 | $0.44 |
| Q4 2024 | 2 | $0.45 | $0.54 | $0.50 |
| Q1 2025 | 2 | $0.33 | $0.45 | $0.39 |
| Q2 2025 | 1 | $0.42 | $0.45 | $0.44 |
| Q3 2025 | 1 | $0.49 | $0.53 | $0.51 |
| Q4 2025 | 1 | $0.53 | $0.57 | $0.55 |
Supernus Pharmaceuticals, Inc. Earnings Date And Information
Supernus Pharmaceuticals, Inc. last posted its earnings results on Monday, November 4th, 2024. The company reported $1.06 earnings per share for the quarter, topping analysts' consensus estimates of $0.39 by $0.67. The company had revenue of 175.69 M for the quarter and had revenue of 607.52 M for the year. Supernus Pharmaceuticals, Inc. has generated $0 earnings per share over the last year ($0.0237 diluted earnings per share) and currently has a price-to-earnings ratio of 33.62. Supernus Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based on prior year's report dates.
Supernus Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/04/2024 | Q3 2024 | $0.39 | $0.70 | 0.31 | $157.35 M | $175.69 M |
| 08/06/2024 | Q2 2024 | $0.31 | $0.36 | 0.05 | $148.83 M | $168.33 M |
| 05/08/2024 | Q1 2024 | $0.39 | $0.00 | -0.39 | $143.64 M | |
| 02/27/2024 | Q4 2023 | $0.41 | $0.02 | -0.39 | $164.31 M | |
| 11/08/2023 | Q3 2023 | $0.13 | -$0.29 | -0.42 | $146.17 M | $153.88 M |
| 08/08/2023 | Q2 2023 | $0.23 | -$0.02 | -0.25 | $143.63 M | $135.56 M |
| 05/09/2023 | Q1 2023 | $0.17 | $0.31 | 0.14 | $153.76 M | |
| 03/09/2023 | Q4 2022 | $0.47 | $167.33 M | |||
| 11/09/2022 | Q3 2022 | $0.03 | $172.48 M | $177.35 M | ||
| 08/08/2022 | Q2 2022 | $0.15 | $164.13 M | $170.05 M | ||
| 05/12/2022 | Q1 2022 | $0.43 | $152.51 M | |||
| 04/13/2022 | Q4 2021 | $0.05 | $159.05 M | |||
| 11/05/2021 | Q3 2021 | $0.41 | $142.12 M | $148.46 M | ||
| 08/06/2021 | Q2 2021 | $0.45 | $135.42 M | $141.33 M | ||
| 05/07/2021 | Q1 2021 | $0.11 | $130.93 M | |||
| 03/08/2021 | Q4 2020 | $0.58 | $143.56 M | |||
| 11/06/2020 | Q3 2020 | $0.76 | $131.00 M | $155.14 M | ||
| 08/17/2020 | Q2 2020 | $0.66 | $98.77 M | $126.73 M | ||
| 05/15/2020 | Q1 2020 | $0.41 | $94.98 M | |||
| 02/28/2020 | Q4 2019 | $0.63 | $100.45 M |
Supernus Pharmaceuticals, Inc. Earnings: Frequently Asked Questions
-
When is Supernus Pharmaceuticals, Inc.'s earnings date?
Supernus Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based off last year's report dates.
-
Did Supernus Pharmaceuticals, Inc. beat their earnings estimates last quarter?
In the previous quarter, Supernus Pharmaceuticals, Inc. (:SUPN) reported $1.06 earnings per share (EPS) to beat the analysts' consensus estimate of $0.39 by $0.67.
-
How can I listen to Supernus Pharmaceuticals, Inc.'s earnings conference call?
The conference call for Supernus Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
-
How can I read Supernus Pharmaceuticals, Inc.'s conference call transcript?
The conference call transcript for Supernus Pharmaceuticals, Inc.'s latest earnings report can be read online.
-
How much revenue does Supernus Pharmaceuticals, Inc. generate each year?
Supernus Pharmaceuticals, Inc. (:SUPN) has a recorded annual revenue of $607.52 M.
-
How much profit does Supernus Pharmaceuticals, Inc. generate each year?
Supernus Pharmaceuticals, Inc. (:SUPN) has a recorded net income of $607.52 M. Supernus Pharmaceuticals, Inc. has generated $0.0241 earnings per share over the last four quarters.
-
What is Supernus Pharmaceuticals, Inc.'s price-to-earnings ratio?
Supernus Pharmaceuticals, Inc. (:SUPN) has a price-to-earnings ratio of 33.62 and price/earnings-to-growth ratio is 0.03.
